Medicare Part D – medicarereport.org

Sunday, December 10, 2023

Latest:

FDA Health Care Finance Legal Actions/Court Decisions Legislative Update Part D/Prescription Drugs

Eileen Cook December 8, 2023December 8, 2023 Bayh-Dole Act of 1980, Biomedical research, Healthcare Costs, March In Rights, Medicare Part D, Prescription drug costs, Prescription Drug Patents

White House proposes to ‘march in’ on patents for costly drugs

(By Sydney Lupkin for NPR) The Biden administration is taking another crack at high prescription drug prices. This time its

CMS Health Care Finance Medicare Advantage

Eileen Cook December 7, 2023December 7, 2023 CMS, medicare, Medicare Advantage, Medicare Part D, Mergers, Older Adults

Is the Medicare Advantage ‘gold rush’ over?

(By Rylee Wilson for Becker’s Hospital Review) The Medicare Advantage gold rush is slowing down, Wall Street Journal columnist David

FDA Legislative Update Part D/Prescription Drugs

Eileen Cook December 7, 2023December 7, 2023 Drug Imports, Drugmakers, FDA, Medicare Part D

Colorado Blames Biden Team and Drugmakers for Delaying Canadian Imports

(By Phil Galewitz for KFF Health News) Colorado officials say their plan to import cheaper medicines from Canada has been

Health Care Finance Part D/Prescription Drugs

Eileen Cook December 6, 2023December 6, 2023 Drug costs, Drug price Transparency, Medicare Part D

The Mark Cuban effect on drug pricing

(By Paige Twenter for Becker’s Hospital Review) In January 2022, entrepreneur and “Shark Tank” star Mark Cuban launched an online

CMS Medicare - General Medicare Advantage Part D/Prescription Drugs

Eileen Cook November 30, 2023November 30, 2023 CMS, medicare, Medicare Advantage, Medicare Advantage Ads, Medicare Part D, Older Adults

Uncle Sam Wants You … to Help Stop Insurers’ Bogus Medicare Advantage Sales Tactics

(By Susan Jaffe for KFF Health News) After an unprecedented crackdown on misleading advertising claims by insurers selling private Medicare

Alzheimer's/Dementia FDA Medicare - General Part D/Prescription Drugs

Eileen Cook November 28, 2023November 28, 2023 Aducanumab, Alzheimer's Disease, ARIA, CMS, Dementia, Donanemab, FDA, Lecanemab Drug, medicare, Medicare Part D, Older Adults

Manufacturers need to be more open about a dangerous Alzheimer’s drug side effect

(By Madhav Thambisetty for STAT) Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision to cover

CMS Medicare - General Medicare Advantage Medigap Part D/Prescription Drugs

Eileen Cook November 27, 2023November 27, 2023 CMS, Healthcare Costs, medicare, Medicare Advantage, Medicare Part D, Older Adults

Medicare Advantage plans are not for everyone

There are many advantages to selecting a Medicare Advantage plan over traditional Medicare. Medicare Advantage plans have a limit on

FDA Health Care Finance National Institutes of Health Part D/Prescription Drugs

Eileen Cook November 17, 2023 Drug Companies, Drug costs, Drug Research, Healthcare Costs, Medicare Part D, National Institutes of Health

Sen. Sanders pushes NIH to rein in drug prices

(By Sydney Lupkin for NPR) Can the National Institutes of Health bring down drug prices? It doesn’t approve new medicines

CMS Health Care Finance Health Care Redesign Legislative Update Medicare - General Part D/Prescription Drugs

Eileen Cook November 15, 2023November 15, 2023 Clawed Back Fee, CMS, Healthcare Costs, medicare, Medicare Part D, PBM Industry, Performance Fees

Biden Administration’s Limit on Drug Industry Middlemen Backfires, Pharmacists Say

(By Arthur Allen for KFF Health News) The Biden administration’s first major step toward imposing limits on the pharmacy benefit

CMS Health Care Finance Medicare - General Medicare Advantage Part D/Prescription Drugs

Eileen Cook November 13, 2023November 13, 2023 CMS, medicare, Medicare Advantage, Medicare Open enrollment, Medicare Part D

It pays to review your choices

We are almost a month into Medicare Open Enrollment for 2024; have you reviewed other plans yet? If you are

← Previous